The Scientists Who Changed Peptide Research

How to read this roster

Scientific history is often told as a list of breakthroughs, but breakthroughs are made by people. This article profiles the researchers whose specific contributions changed peptide science — organized roughly in the order their work built on one another. Some names are famous; others are less well known outside the field but no less consequential. Together they answer a simple question: who actually made modern peptide medicine possible?

A note on scope. Our companion article, the pioneers of peptide science, profiles four field-defining figures — Merrifield, Guillemin, Schally, and DiMarchi — in depth. To avoid repetition, this roster summarizes those figures briefly and links to the fuller treatment, while spending more time on scientists not covered there, such as Sanger, du Vigneaud, Yalow, Mutt, and the GLP-1 biologists. For the technique-and-milestone chronology that frames all of these careers, see the history of peptide research.

Frederick Sanger: reading the peptide chain

Frederick Sanger is one of the very few people to win two Nobel Prizes in the same category. The first, in Chemistry in 1958, was for determining the complete amino-acid sequence of insulin. Before Sanger, it was not even certain that a protein had a single, fixed sequence rather than some variable arrangement. By painstakingly breaking insulin into fragments and reconstructing their order, he proved that proteins are defined chemical entities with an exact sequence of amino acids.

The importance of this for peptide research is hard to overstate. If peptides and proteins have precise sequences, then they can, in principle, be written down, compared, and rebuilt. Sanger's insulin work gave the field its first fully sequenced protein and made the concept of molecular identity concrete — an idea at the heart of how researchers today verify what a peptide actually is. (His second Nobel, in 1980, was for methods of sequencing DNA, a separate revolution.)

Sanger's legacy connects directly to modern quality science. The reason it matters whether a research peptide is the correct molecule — the concept of identity confirmed by mass spectrometry — descends conceptually from Sanger's demonstration that sequence is everything. Understanding a molecule's exact composition is the difference between studying the intended peptide and studying an impurity.

Du Vigneaud and Yalow: building and measuring

Vincent du Vigneaud answered the question of whether a natural peptide hormone could be built in the laboratory. In the 1950s he and his colleagues synthesized oxytocin — a nine-amino-acid peptide — and confirmed the synthetic molecule was biologically active, matching the natural hormone. This was the first synthesis of a polypeptide hormone, and du Vigneaud received the 1955 Nobel Prize in Chemistry for his work on biologically important sulfur-containing compounds. His achievement proved peptides were not only extractable from tissue but constructible from scratch.

Rosalyn Yalow, working with Solomon Berson, solved a different and equally fundamental problem: measurement. Many peptide hormones circulate in quantities so small they had been effectively invisible. Yalow and Berson's radioimmunoassay (RIA) used antibodies and radioactive tracers to detect these trace amounts with unprecedented sensitivity. Yalow received the 1977 Nobel Prize in Physiology or Medicine for the development of radioimmunoassays of peptide hormones — and was one of the few women honored in the sciences in her era, having built the technique that made endocrinology's golden age possible.

Placed together, these two scientists supplied the second and third of peptide science's foundational abilities: du Vigneaud proved peptides could be made, and Yalow proved they could be measured. Combined with Sanger's demonstration that they could be read, the field now had the essential capabilities — read, build, measure — on which everything else would depend.

Bruce Merrifield: making peptides routinely buildable

Du Vigneaud proved a peptide hormone could be synthesized, but early synthesis in solution was so laborious that building anything longer than a short chain could take months. Bruce Merrifield changed that in 1963 with solid-phase peptide synthesis (SPPS): anchor the first amino acid to an insoluble bead, then grow the chain outward, washing away byproducts between steps. This turned an artisanal ordeal into a fast, repeatable, automatable cycle, and earned Merrifield the 1984 Nobel Prize in Chemistry.

Because Merrifield is profiled in depth in the pioneers of peptide science, we keep this brief — but his place in any roster is non-negotiable. SPPS is the reason peptides can be produced consistently and at scale, and it is the method behind the great majority of research peptides made today. Just as importantly, the ability to synthesize peptides routinely let researchers make deliberate variants, systematically swapping amino acids to study how structure relates to function — the engine of modern peptide drug design.

Guillemin, Schally, and Mutt: the hormone hunters

Once peptides could be read, built, and measured, the next great task was discovery: finding the body's own peptide hormones and figuring out what they do. Roger Guillemin and Andrew Schally, working as intense rivals, proved that the hypothalamus controls the pituitary — and much of the endocrine system — through tiny peptide releasing hormones. They isolated key hormones including TRH, GnRH (LHRH), and somatostatin, founding neuroendocrinology and sharing the 1977 Nobel Prize (alongside Yalow). Both are profiled more fully in the pioneers article; their discoveries led directly to real medicines such as GnRH and somatostatin analogs.

Less famous to the public, but pivotal, is Viktor Mutt, a Swedish biochemist who spent decades isolating and characterizing the peptide hormones of the gastrointestinal tract. Working with large quantities of intestinal tissue, Mutt and his collaborators purified and sequenced a long list of gut peptides. This gut-hormone work is a crucial and often overlooked branch of the story, because the incretin hormones behind today's most important metabolic drugs — including GLP-1 — originate in the gut. Without the tradition of careful gut-peptide chemistry that Mutt exemplified, the incretin era would have had far less to build on.

Together these hormone hunters mapped where the body's peptide signals come from — the brain and the gut — and established the template that recurs throughout peptide medicine: identify a natural peptide, understand its physiological role, then engineer an improved analog into a therapy. To see how their discoveries connect to receptor biology, see understanding peptide receptors.

The GLP-1 biologists: Habener, Mojsov, Drucker, and Holst

The modern incretin revolution rests on a group of researchers who, across the 1980s and beyond, worked out the biology of glucagon-like peptide-1 (GLP-1). Joel Habener and Svetlana Mojsov, at Massachusetts General Hospital and Harvard, were central to identifying the biologically active form of GLP-1 and showing it stimulates insulin secretion in a glucose-dependent manner. Mojsov's careful chemistry in defining the truncated, active fragment was essential to understanding which molecule actually mattered.

Daniel Drucker, whose early career included work in Habener's laboratory, went on to become one of the most influential figures in incretin biology, elucidating the physiological actions of GLP-1 and related gut peptides on insulin, appetite, and the gut over decades of research. In Europe, Jens Juul Holst independently made foundational contributions to GLP-1 physiology, including its effects on insulin secretion and appetite. This transatlantic body of work established GLP-1 as a hormone with powerful, therapeutically relevant effects on glucose and body weight.

Their collective discovery came with a challenge: native GLP-1 is degraded within minutes by the enzyme DPP-4, making the natural hormone impractical as a drug. Solving that durability problem became the central task of GLP-1 drug development. For the underlying physiology these scientists uncovered, see GLP-1 biology, and for the broader incretin picture, GIP biology and glucagon biology.

Knudsen and DiMarchi: from biology to medicine

Understanding GLP-1 was one thing; turning it into a durable, once-weekly medicine was another. Lotte Bjerre Knudsen, a scientist at Novo Nordisk, was a driving force in translating GLP-1 biology into practical drugs. Her work centered on extending the hormone's short half-life — notably through fatty-acid attachment (lipidation) that promotes binding to albumin in the blood, dramatically slowing clearance. This half-life-extension strategy is what made long-acting GLP-1 receptor agonists possible, and it is explored in our guide to long-acting peptides.

Richard DiMarchi, a chemist with major roles in both industry and academia, is most associated with the next leap: engineering single peptides that activate more than one receptor at once. His work on engineered insulins and, especially, on multi-receptor agonist peptides underpins the newest generation of metabolic medicines — dual and triple agonists that amplify metabolic benefit beyond any single-target drug. DiMarchi is profiled in depth in the pioneers of peptide science; the design philosophy behind his work is the subject of the science of multi-agonist peptides.

Together, Knudsen and DiMarchi represent the final stage of the roster: the translation of decades of biology and chemistry into medicines used by millions. For the peptides that resulted, see the overviews of semaglutide, tirzepatide, and retatrutide. Their careers demonstrate that discovering a hormone is only the beginning — engineering it into a stable, potent, conveniently dosed drug is a distinct and formidable science of its own.

The roster at a glance

The table below summarizes the scientists profiled here and the specific contribution each made. Read top to bottom, it traces the same arc as the history of peptide research: first the abilities to read, build, and measure peptides; then the discovery of the body's own peptide hormones in the brain and gut; and finally the translation of that knowledge into modern medicines.

No roster is complete — peptide science advanced through the work of many hundreds of researchers, and any short list inevitably leaves out important contributors. What this selection illustrates is the pattern of progress: each scientist removed a specific barrier, and each barrier removed exposed the next. For the wider narrative and the technique-by-technique timeline, continue with the history of peptide research; for the concentrated four-person account, see the pioneers of peptide science.

What their work means for peptides today

The careers profiled here are not just history — they define the priorities of anyone working with peptides now. Sanger's demonstration that sequence is identity is the reason identity confirmation matters; du Vigneaud and Merrifield's synthesis work is why peptides can be made purely and reproducibly; Yalow's measurement legacy underlies the analytical rigor of modern characterization. Studying these scientists is, in effect, studying why quality and verification are non-negotiable in peptide science.

That heritage has practical echoes. The emphasis on knowing exactly what a molecule is, and how pure it is, is the same logic behind verifying research material through documentation such as certificates of analysis and choosing carefully characterized sources — see, for example, the Base Peptides review and our guidance on why peptides are research-only. The scientists in this article turned peptides into a rigorous, reproducible science; honoring their legacy means holding to those same standards.

Finally, this roster explains why peptide research is accelerating rather than plateauing. The GLP-1 biologists and drug developers showed that combining deep physiological understanding with clever engineering can produce genuinely transformative medicines. That template — biology plus engineering — now drives work on multi-agonist peptides, long-acting formulations, and new delivery routes. The people change, but the pattern they established endures.